The project proposes furthering the development of patent-protected non-toxic, targeted, protein-based MRI contrast agents into marketable products. We expect this project to evolve into the incorporation of a start-up to exploit the technology, and the successful candidate to become the Chief Technology Officer of the venture. The main objective of this position will be to lead the development of the technology into the successive stages required to reach the market in parallel with the start-up development. The successful candidate will work jointly with the Biomolecular Nanotechnology group and the Technology Transfer Office of CIC biomaGUNE, under the supervision of Dr. Aitziber López-Cortajarena

Organización/Organization:

CIC biomaGUNE

Fecha límite/Deadline:

15/12/2022